Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai Allist Pharmaceuticals Co | Shanghai | Healthcare | Biotechnology & Medical Research | 30% | CN¥3.22KCr | 19.8x | 0.15 | CN¥71.60 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.7% Upside | Upgrade to Pro+ | |
Beigene | Shanghai | Healthcare | Biotechnology & Medical Research | 7.5% | CN¥17.38KCr | -0.3x | -1.77 | CN¥195 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
Sichuan Biokin Pharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -8.6% | CN¥7.25KCr | 21.3x | 0.02 | CN¥180.81 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dizal Jiangsu Pharmaceutical | Shanghai | Healthcare | Biotechnology & Medical Research | -10.9% | CN¥1.74KCr | -20.2x | -0.97 | CN¥41.75 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.1% Upside | Upgrade to Pro+ | |
Jiangsu Asieris Pharmaceuticals | Shanghai | Healthcare | Biotechnology & Medical Research | -11.8% | CN¥399Cr | -9x | 0.58 | CN¥7.11 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.8% Upside | Upgrade to Pro+ | |
Chongqing Baiya | Shenzhen | Consumer Non-Cyclicals | Personal & Household Products & Services | -12.6% | CN¥972Cr | 35.5x | 1.91 | CN¥22.63 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.9% Upside | Upgrade to Pro+ | |
Dongxing Securities | Shanghai | Financial | Investment Banking & Investment Services | -12.6% | CN¥3.62KCr | 27.8x | 0.14 | CN¥11.20 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -24.1% Downside | Upgrade to Pro+ | |
Ruida | Shenzhen | Financial | Investment Banking & Investment Services | -13.8% | CN¥645Cr | 20.1x | 0.44 | CN¥14.49 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18.6% Downside | Upgrade to Pro+ | |
Shandong Cvicse Middleware | Shanghai | Technology | Software & IT Services | -14.9% | CN¥275Cr | 32.8x | 0.63 | CN¥32.30 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures | Shenzhen | Financial | Investment Banking & Investment Services | -18% | CN¥812Cr | 110.7x | 1.39 | CN¥9.87 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
RemeGen | Shanghai | Healthcare | Biotechnology & Medical Research | -19% | CN¥1.26KCr | -5.5x | 0.48 | CN¥28.47 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Chongqing Genrix Biopharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -19.4% | CN¥916Cr | -11.6x | -1.34 | CN¥24.99 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabwell Shanghai Bioscience | Shanghai | Healthcare | Biotechnology & Medical Research | -28% | CN¥660Cr | -6.4x | 0.47 | CN¥16.52 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Innovita Biological Tech | Shanghai | Healthcare | Healthcare Equipment & Supplies | -30.1% | CN¥410Cr | 13.3x | 0.07 | CN¥30.05 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |